WO2000041674A1 - Utilisation d'un extrait d'un vegetal du genre rosmarinus dans des compositions destinees a traiter les signes cutanes du vieillissement - Google Patents
Utilisation d'un extrait d'un vegetal du genre rosmarinus dans des compositions destinees a traiter les signes cutanes du vieillissement Download PDFInfo
- Publication number
- WO2000041674A1 WO2000041674A1 PCT/FR2000/000034 FR0000034W WO0041674A1 WO 2000041674 A1 WO2000041674 A1 WO 2000041674A1 FR 0000034 W FR0000034 W FR 0000034W WO 0041674 A1 WO0041674 A1 WO 0041674A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- composition
- plant
- intended
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the invention relates to the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition intended to treat, preventively and / or curatively, the skin signs of aging .
- the extract or the composition are intended to stimulate restructuring and / or inhibit the degradation of the skin and / or mucous membranes by stimulating the synthesis of collagen and / or by inhibiting collagenases.
- the invention also relates to a method of cosmetic treatment of the skin and / or mucous membranes.
- Human skin is made up of two compartments, namely a surface compartment, the epidemic, and a deep compartment, the dermis.
- the natural human epidermis is mainly composed of three types of cells which are the keratinocytes, very majority, the melanocytes and the Langerhans cells. Each of these cell types contributes by its own functions to the essential role played in the body by the skin.
- the dermis provides the epidermis with solid support. It is also its nourishing element. It mainly consists of fibroblasts and an extracellular matrix itself composed mainly of collagen, elastin and a substance, known as the fundamental substance, components synthesized by the fibroblast. There are also leukocytes, mast cells or tissue macrophages. It is also crossed by blood vessels and nerve fibers. In normal skin, that is to say non-pathological or scarring, the fibroblast is in a quiescent state, that is to say non-proliferative, not very active from a metabolic point of view and not mobile.
- Collagen fibers which ensure the solidity of the dermis.
- Collagen fibers are made up of fibrils sealed to each other, thus forming more than ten different types of structures.
- the solidity of the dermis is largely due to the entanglement of collagen fibers packed against each other in all directions. Collagen fibers participate in the elasticity and tone of the skin and / or mucous membranes.
- the collagen fibers are constantly renewed, but this renewal decreases with age, which leads to thinning of the dermis.
- This thinning of the dermis is also due to pathological causes such as hypersecretion of corticosteroid hormones, certain diseases (Marfan syndrome, Ehiers-Danlos syndrome) or vitamin deficiencies (scurvy).
- pathological causes such as hypersecretion of corticosteroid hormones, certain diseases (Marfan syndrome, Ehiers-Danlos syndrome) or vitamin deficiencies (scurvy).
- extrinsic factors such as ultraviolet rays, tobacco or certain treatments (glucocorticoids, vitamin D and derivatives for example) also have an effect on the skin and its collagen level.
- collagen fibers are sensitive to certain enzymes called collagenases. Degradation of collagen fibers results in the appearance of soft, wrinkled skin that humans, preferring the appearance of smooth and taut skin, have always sought to combat.
- Collagenases are part of a family of enzymes called metalloproteinases (MMPs) which are themselves members of a family of proteolytic enzymes (endoproteases) which have a zinc atom coordinated to 3 cysteine residues and a methionine in their active site and which degrade the macromolecular components of the extracellular matrix and basal laminae at neutral pH (collagen, elastin, etc.).
- MMPs metalloproteinases
- endoproteases proteolytic enzymes
- these enzymes are present, but weakly expressed, in normal physiological situations such as organ growth and tissue renewal.
- the family of metalloproteinases is made up of several well-defined groups based on their similarities in terms of structure and substrate specificity (see Woessner JF, Faseb Journal, vol. 5, 1991, 2145).
- collagenases intended for degrading fibrillar collagens MMP-1 or interstitial collagenase, MMP-8 or neutrophil collagenase, MMP-13 or collagenase 3
- gelatinases which degrade collagen type IV or any denatured form of collagen MMP-2 or gelatinase A (72 kDa), MMP-9 or gelatinase B (92 kDa)
- stromelysins MMP-3 including the broad spectrum of activity targets proteins in the extracellular matrix such as glycoproteins (fibronectin, laminin), proteoglycans, etc., or even membrane metalloproteinases.
- Prolonged exposure to ultraviolet radiation has the effect of stimulating the expression of collagenases, particularly MMP-1. This is one of the components of photo-induced skin aging.
- the main modifications concerning the dermis are a reduction in the collagen level and the dermal thickness. This leads in menopausal women to thinning of the skin and / or mucous membranes. The woman then feels a feeling of "dry skin” or of skin that pulls and there is an accentuation of fine wrinkles and fine lines on the surface. The skin has a rough appearance on palpation. Finally, the skin has reduced flexibility.
- One of the aims of the present invention is therefore to be able to have a new product which has a stimulating effect on the synthesis of collagen, an effect which inhibits collagenases and, if possible, no significant side effects.
- an extract of at least one plant of the genus Rosmarinus has an activity stimulating the synthesis of collagen and an activity inhibiting the activity of collagenases.
- Plants of the genus Rosmarinus in addition to their taste and odor properties, are known for their anti-inflammatory effects.
- the activity stimulating the synthesis of collagen and the activity inhibiting the activity of collagenases of an extract of at least one plant of the genus Rosmarinus have never been described.
- the primary object of the invention is the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition, the extract or the composition being intended to treat, so preventive and / or curative, the skin signs of aging.
- extract of at least one plant of the genus Rosmarinus is understood to mean both a crude mixture of parts of the plant roughly reduced to pieces and of the extraction solvent as well as elaborate preparations of the active principles dissolved during the extraction.
- active principle any molecule or composition capable of modifying or modulating the functioning of at least one given biological system.
- cutaneous signs of aging means any modification of the external appearance of the skin due to aging, whether chronobiological and / or photoinduced, such as for example wrinkles and fine lines, withered skin, mole skin, thinned skin, the lack of elasticity and / or tone of the skin, but also all internal modifications of the skin which do not systematically result in a modified external appearance, such as for example any internal degradations of the skin, particularly of collagen, consecutive to exposure to ultraviolet radiation.
- a second object of the invention is the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition, the extract or the composition being intended to stimulate the synthesis of collagen .
- a third object of the invention is the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition, the extract or the composition being intended to inhibit the expression of proteases extracellular matrix, particularly metalloproteinases and even more particularly metalloproteinase type 1.
- a fourth object of the invention is the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition, the extract or the composition being intended to treat cutaneous lesions linked to menopause.
- a fifth object of the invention is the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition, the extract or the composition being intended for combating fine lines and wrinkles .
- a sixth object of the invention is the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition, the extract or the composition being intended for combating withered skin.
- the seventh subject of the invention is the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition, the extract or the composition being intended for combating soft skin.
- the eighth object of the invention is the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition, the extract or the composition being intended for combating thinned skin.
- the ninth object of the invention is the use of at least one extract of at least one plant of the genus Rosmarinus in or for the preparation of a composition, the extract or the composition being intended to combat the lack of elasticity and / or skin tone.
- the extract of at least one plant of the genus Rosmarinus used according to the invention can be obtained from plant material obtained from a whole plant or part of a plant such as the leaves, stems, flowers, petals, roots or still dedifferentiated cells.
- dedifferentiated plant cells any plant cell having none of the characteristics of a particular specialization and capable of living by itself and not in dependence on other cells.
- the whole plant is used, particularly the stem and / or the leaves, very particularly the leaves.
- the extract of at least one plant of the genus Rosmarinus can be any extract prepared from any plant material derived from at least one plant of the genus Rosmarinus cultivated in vivo or derived from culture in vitro.
- in vivo culture means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
- in vitro culture means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant.
- the selection pressure imposed by physicochemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material available throughout the year, unlike plants cultivated in vivo.
- a plant of the genus Rosmarinus is used which is grown in vivo.
- the Rosmarinus officinalis species comprises two varieties which are Rosmarinus tenuifolius and Rosmarinus latifolius.
- the extract of the invention can be prepared from plant material from the Rosmarinus officinalis species, whatever the variety.
- Any extraction method known to those skilled in the art can be used to prepare the extract according to the invention. Mention may, in particular, be made of alcoholic extracts, in particular ethanolic or hydroalcoholic extracts.
- the extract is an aqueous extract.
- the plant material is ground in a cold aqueous solution and in a second step, the particles in suspension are removed from the aqueous solution resulting from the first step.
- This aqueous solution corresponds to the extract.
- the aqueous solution from the second step is sterilized.
- This extract can then be lyophilized.
- the first step can advantageously be replaced by a simple freezing operation of the plant tissues (for example at -20 ° C or even at -180 ° C in liquid nitrogen), followed by an aqueous extraction repeating the second and third steps above described.
- the cold treatment makes it possible to freeze the enzymatic activities, the sterilizing filtration avoids the degradation of the active ingredients by the microorganisms of the environment.
- the water vehicle is compatible with ex vivo receptors and facilitates cosmetic or pharmaceutical formulations.
- the extract obtained can be fractionated by any known fractionation method making it possible to eliminate the oxidases and in particular the polyphenoloxidase.
- the extract can also be stabilized. Any known stabilization method can be used according to the invention. It is possible, for example, to stabilize the extract of the invention by bubbling nitrogen through to eliminate the dissolved oxygen or alternatively by adding cysteine and / or sulfur derivatives to a final concentration of between 0.5 g / l and 10 g / l and preferably between 1 g / l and 2.5 g / l.
- the extract alone can constitute the active principle of the compositions of the invention.
- the extract does not contain rosmarinic acid.
- An example of preparation of extract usable according to the invention is given elsewhere in the examples.
- the amount of extract usable according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
- an extract as defined above can be used in an amount representing from 0.001% to 20% of the total weight of the composition and preferably in an amount representing from 0.01% to 10% of the total weight of the composition.
- the present invention further relates to a cosmetic treatment process for the skin intended to stimulate the synthesis of collagen and / or treat cutaneous lesions linked to age and / or menopause and / or fight against thinning of the skin. dermis and / or combat the appearance of soft and / or wrinkled skin, characterized in that a cosmetic composition comprising at least extract of, is applied to the skin, to the hair, and / or to the mucous membranes. at least one plant of the genus Rosmarinus.
- the cosmetic treatment process of the invention can be implemented in particular by applying the cosmetic compositions as defined above, according to the usual technique for using these compositions. For example: application of creams, gels, serums, lotions, milks, shampoos or anti-sun compositions, on the skin, or on the hair or application of toothpaste on the gums.
- compositions illustrate the invention without limiting it in any way.
- proportions indicated are percentages by weight.
- Example 1 Preparation of an extract of Rosmarinus officinalis:
- the powder obtained is mixed with 5 liters of 0.05 M phosphate buffer at pH 8.5.
- the whole is stirred for 30 minutes at 4 ° C, then centrifuged at 10,000 G at 4 ° C.
- the supernatant is filtered at 0.22 ⁇ m (sterilizing filtration).
- the extract is then fractionated by ultrafiltration on a Sartorius type membrane in order to eliminate the oxidation phenomena therefrom.
- the extract is then lyophilized. This gives 29.5 grams of active extract called "lyophilized extract”.
- Example 2 Effect of the extract of Example 1 on the synthesis of collagen: The study is carried out by measuring the incorporation of radioactive praline in cultures of normal human dermal fibroblasts.
- the fibroblast cultures are carried out according to conventional cell culture methods, namely in MEM / M199 medium sold by the company Gibco, in the presence of sodium bicarbonate (1.87 mg / ml) of L-glutamine (2 mM), penicillin (50 IU / ml) and 10% fetal calf serum (Gibco).
- the test is carried out on cell cultures at 80% confluence in a 24-hole plate.
- the extract of Example 1 lyophilized extract titrated at 25 mg / ml of water to obtain a 100% stock solution
- 0.2%, 1% and 2% is brought into contact with cells for 48 hours.
- Labeling with tritiated praline (L- [2,3- 3 H] -proline sold by Amersham, 33 ⁇ Ci / ml) is carried out for 24 hours.
- the level of incorporated tritiated praline is measured at the end of the test by acid precipitation of the proteins on filters and counting in liquid scintillation.
- a positive control (vitamin C at 20 ⁇ g / ml) known to stimulate the synthesis of collagen is introduced into the test as a reference.
- cpm counts per minute
- p confidence interval calculated according to the Dunett method.
- Example 3 Effect of the extract of Example 1 on the expression of collagenases.
- the study makes it possible to evaluate the effectiveness of a product in inhibiting the induction of transcription of the collagenase gene by ultraviolet radiation.
- the test is carried out on Hela cells (ATCC CCL2) in which the promoter of the collagenase 1 gene (3.8 kB) clones upstream of the chloramphenicol acetyltransferase (CAT) gene has been introduced.
- ATCC CCL2 Hela cells
- CAT chloramphenicol acetyltransferase
- UVB ultraviolet B radiation
- the cells are then brought into contact for 2 hours with the extract of Example 1 at concentrations varying from 0.05% to 0.5%.
- the CAT assay is carried out using a "CAT-Elisa" kit sold by the company Boehringer, according to the supplier's instructions.
- a "base rate" of the expression of CAT is measured in cells which have received neither ultraviolet radiation nor treatment with the product to be tested.
- the test results, presented in the attached table, are expressed relative to the base rate (100%), as a percentage of activation or inhibition of the expression of the CAT gene.
- Example 4 Examples of formulations illustrating the invention and particularly the compositions according to the invention combining at least one extract of Rosmarinus officinalis. These compositions were obtained by simple mixing of the various components.
- Composition 1 Make-up removing lotion for the face
- Composition 2 Shampoo
- Hydroxypropylcellulose (Klucel H ® sold by the company Hercules) 1.00%
- Composition 3 Face care cream (oil in water emulsion)
- Polysorbate 60 (Tween 60 ® sold by the company ICI) 1.00%
- Composition 4 Skin gel Extract from Example 1 0.50%
- Hydroxypropylcellulose (Klucel H ® sold by the company Hercules) 1.00%
- Composition 5 Gel for facial care
- Composition 6 Gel Extract of Example 1 1, 00%
- Hydroxypropylcellulose (Klucel H ® sold by Hercules) 1.00% Antioxidant 0.05% Lidocaine hydrochloride 2.00% Isopropanol 40.00% Preservative 0.30% Water qs 100.00%
- Composition 7 Sun erythema care cream (oily oil emulsion - ddaanns ⁇ > - water)
- Polysorbate 60 (Tween 60 ® sold by the company ICI) 1.00%
- Composition 8 Anti-wrinkle face cream (emulsion ⁇ hhuuiillee // eeaauu))
- Composition 9 Lotion Extract from Example 1 0.50% Giycolic acid 50.00% Hydroxypropylcellulose (Klucel H ® sold by the company Hercules) 0.05% Preservative 0.30%
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU30519/00A AU3051900A (en) | 1999-01-15 | 2000-01-10 | Use of a plant extract of the genus rosmarinus in compositions for treating ageing skin symptoms |
JP2000593288A JP4441123B2 (ja) | 1999-01-15 | 2000-01-10 | 加齢皮膚の徴候を処置するための組成物におけるロスマリヌス属の植物抽出物の使用 |
CA002360488A CA2360488A1 (fr) | 1999-01-15 | 2000-01-10 | Utilisation d'un extrait d'un vegetal du genre rosmarinus dans des compositions destinees a traiter les signes cutanes du vieillissement |
EP00900546A EP1146850A1 (fr) | 1999-01-15 | 2000-01-10 | Utilisation d'un extrait d'un vegetal du genre rosmarinus dans des compositions destinees a traiter les signes cutanes du vieillissement |
US09/904,560 US20020048594A1 (en) | 1999-01-15 | 2001-07-16 | Rosmarinus extracts for inhibiting/treating skin aging |
US11/812,816 US20080003311A1 (en) | 1999-01-15 | 2007-06-21 | Rosmarinus extracts for inhibiting/treating skin aging |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9900406A FR2788435B1 (fr) | 1999-01-15 | 1999-01-15 | Utilisation d'un extrait d'un vegetal du genre rosmarinus dans des compositions destinees a traiter les signes cutanes du vieillissement |
FR99/00406 | 1999-01-15 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09869740 A-371-Of-International | 2001-07-03 | ||
US09/904,560 Continuation US20020048594A1 (en) | 1999-01-15 | 2001-07-16 | Rosmarinus extracts for inhibiting/treating skin aging |
US10/391,055 Continuation US6887059B2 (en) | 1999-01-18 | 2003-03-17 | Lever-mechanism motor or pump |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000041674A1 true WO2000041674A1 (fr) | 2000-07-20 |
Family
ID=9540903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/000034 WO2000041674A1 (fr) | 1999-01-15 | 2000-01-10 | Utilisation d'un extrait d'un vegetal du genre rosmarinus dans des compositions destinees a traiter les signes cutanes du vieillissement |
Country Status (7)
Country | Link |
---|---|
US (3) | US20020048594A1 (fr) |
EP (1) | EP1146850A1 (fr) |
JP (1) | JP4441123B2 (fr) |
AU (1) | AU3051900A (fr) |
CA (1) | CA2360488A1 (fr) |
FR (1) | FR2788435B1 (fr) |
WO (1) | WO2000041674A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004004673A1 (fr) * | 2002-07-08 | 2004-01-15 | Coty B.V. | Produit cosmetique anti-vieillissement cutane |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2815863B1 (fr) * | 2000-10-26 | 2003-02-28 | Oreal | Composition comprenant l'association d'au moins un extrait d'au moins un vegetal du genre rosmarinus et d'au moins un carotenoide |
WO2006041526A1 (fr) * | 2004-10-07 | 2006-04-20 | Access Business Group International Llc | Composition contenant un extrait de plante de rosmarinus officinalis, un extrait de plante d'alpinia et une enzyme de reparation de l'adn |
US7758878B2 (en) | 2003-10-10 | 2010-07-20 | Access Business Group International Llc | Cosmetic treatment system and methods |
JP2007508320A (ja) * | 2003-10-10 | 2007-04-05 | アクセス ビジネス グループ インターナショナル エルエルシー | マンネンロウ(Rosmarinusofficinalis)植物抽出物、センテラ(Centella)、ムラサキバレンギク(Echinacea)又はアルピニア(Alpinia)植物抽出物、及びDNA修復酵素を含む組成物 |
JP4571952B2 (ja) * | 2004-02-05 | 2010-10-27 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | 抗アレルギー組成物及び関連方法 |
PT1890710E (pt) * | 2005-05-13 | 2012-02-06 | Nestec Sa | Produção de glucosamina a partir de espécies de plantas |
EP1890709B1 (fr) * | 2005-05-13 | 2011-11-09 | Nestec S.A. | Production de glucosamine végétal |
EP1917960A1 (fr) * | 2006-11-06 | 2008-05-07 | Nestec S.A. | Effects biologiques améliorée de l'acide rosmarinique |
EP2052721A1 (fr) * | 2007-10-22 | 2009-04-29 | DSMIP Assets B.V. | Utilisation du carnosol pour réparation du cartilage |
CN104490678B (zh) * | 2014-12-09 | 2017-12-01 | 湖南省雅迭香科技有限公司 | 一种迷迭香纯露化妆水及其制备方法 |
CA2972768C (fr) * | 2014-12-30 | 2020-06-09 | Graham Robert Drummond | Amelioration de la stabilite a basse temperature d'agents ameliorant l'ecoulement de fluide |
EP3332765A4 (fr) * | 2015-08-04 | 2020-10-21 | Shiseido Company Ltd. | Agent contenant une substance attirant les cellules souches graisseuses pour remédier au relâchement ou au vieillissement cutané provoqué par la cavitation dermique |
US10182981B2 (en) * | 2015-12-08 | 2019-01-22 | The Procter & Gamble Company | Method of regulating a skin condition |
US10537515B2 (en) * | 2015-12-08 | 2020-01-21 | The Procter & Gamble Company | Personal care composition and method of making the same |
WO2017100112A1 (fr) | 2015-12-08 | 2017-06-15 | The Procter & Gamble Company | Composition de soin de la peau contenant de l'abricot bâtard |
WO2017100109A1 (fr) * | 2015-12-08 | 2017-06-15 | The Procter & Gamble Company | Procédé de régulation d'une affection de tissu kératinique de mammifère |
CN107802547A (zh) * | 2017-12-06 | 2018-03-16 | 湖南省雅迭香科技有限公司 | 一种迷迭香洗发露 |
EP3817755A4 (fr) * | 2018-07-03 | 2022-04-20 | Mary Kay Inc. | Compositions topiques de relaxation musculaire et procédés |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63162611A (ja) * | 1986-12-24 | 1988-07-06 | Pola Chem Ind Inc | 美肌化粧料 |
FR2652001A1 (fr) * | 1989-09-20 | 1991-03-22 | Andary Claude | Composition dermato-cosmetique a base d'acide rosmarinique presentant des proprietes de filtre solaire et d'agent anti-inflammatoire. |
FR2663848A1 (fr) * | 1990-07-02 | 1992-01-03 | Raquet Jean Paul | Procede de fabrication de produits de soins du corps et produits realises suivant le procede. |
DE4129331A1 (de) * | 1991-09-04 | 1993-03-11 | Visuvia Chemisch Pharmazeutisc | Kosmetisches mittel |
US5393526A (en) * | 1994-02-07 | 1995-02-28 | Elizabeth Arden Company, Division Of Conopco, Inc. | Cosmetic compositions |
JPH10291929A (ja) * | 1997-04-21 | 1998-11-04 | Nagase & Co Ltd | シワ形成抑制皮膚外用剤 |
WO1999030682A1 (fr) * | 1997-12-17 | 1999-06-24 | Color Access, Inc. | Melange antioxydant |
JPH11246337A (ja) * | 1998-03-03 | 1999-09-14 | Shiseido Co Ltd | 抗老化剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3558349B2 (ja) * | 1992-04-24 | 2004-08-25 | 御木本製薬株式会社 | 美白化粧料 |
US5939078A (en) * | 1995-11-20 | 1999-08-17 | Kao Corporation | Wrinkle-care product |
FR2746641B1 (fr) * | 1996-03-27 | 1998-06-05 | Oreal | Utilisation d'un extrait d'au moins une iridacee dans le traitement des rides |
JPH1072336A (ja) * | 1996-06-28 | 1998-03-17 | Kao Corp | コラーゲンゲル収縮促進剤 |
JPH10330221A (ja) * | 1997-06-02 | 1998-12-15 | Pola Chem Ind Inc | 真皮コラーゲン線維束正常化剤 |
JPH11106347A (ja) * | 1997-08-07 | 1999-04-20 | Shiseido Co Ltd | 免疫賦活剤 |
FR2815863B1 (fr) * | 2000-10-26 | 2003-02-28 | Oreal | Composition comprenant l'association d'au moins un extrait d'au moins un vegetal du genre rosmarinus et d'au moins un carotenoide |
-
1999
- 1999-01-15 FR FR9900406A patent/FR2788435B1/fr not_active Expired - Fee Related
-
2000
- 2000-01-10 EP EP00900546A patent/EP1146850A1/fr not_active Withdrawn
- 2000-01-10 WO PCT/FR2000/000034 patent/WO2000041674A1/fr active Application Filing
- 2000-01-10 JP JP2000593288A patent/JP4441123B2/ja not_active Expired - Fee Related
- 2000-01-10 AU AU30519/00A patent/AU3051900A/en not_active Abandoned
- 2000-01-10 CA CA002360488A patent/CA2360488A1/fr not_active Abandoned
-
2001
- 2001-07-16 US US09/904,560 patent/US20020048594A1/en not_active Abandoned
-
2003
- 2003-05-05 US US10/428,783 patent/US20040037901A1/en not_active Abandoned
-
2007
- 2007-06-21 US US11/812,816 patent/US20080003311A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63162611A (ja) * | 1986-12-24 | 1988-07-06 | Pola Chem Ind Inc | 美肌化粧料 |
FR2652001A1 (fr) * | 1989-09-20 | 1991-03-22 | Andary Claude | Composition dermato-cosmetique a base d'acide rosmarinique presentant des proprietes de filtre solaire et d'agent anti-inflammatoire. |
FR2663848A1 (fr) * | 1990-07-02 | 1992-01-03 | Raquet Jean Paul | Procede de fabrication de produits de soins du corps et produits realises suivant le procede. |
DE4129331A1 (de) * | 1991-09-04 | 1993-03-11 | Visuvia Chemisch Pharmazeutisc | Kosmetisches mittel |
US5393526A (en) * | 1994-02-07 | 1995-02-28 | Elizabeth Arden Company, Division Of Conopco, Inc. | Cosmetic compositions |
EP0666072A2 (fr) * | 1994-02-07 | 1995-08-09 | Unilever Plc | Compositions cosmétiques |
JPH10291929A (ja) * | 1997-04-21 | 1998-11-04 | Nagase & Co Ltd | シワ形成抑制皮膚外用剤 |
WO1999030682A1 (fr) * | 1997-12-17 | 1999-06-24 | Color Access, Inc. | Melange antioxydant |
JPH11246337A (ja) * | 1998-03-03 | 1999-09-14 | Shiseido Co Ltd | 抗老化剤 |
Non-Patent Citations (4)
Title |
---|
CALABRESE V. ET AL., J.APPL.COSMETOL., vol. 16, no. 4, 1998, pages 155 - 164, XP002118851 * |
PATENT ABSTRACTS OF JAPAN vol. 012, no. 438 (C - 544) 17 November 1988 (1988-11-17) * |
PATENT ABSTRACTS OF JAPAN vol. 199, no. 902 26 February 1999 (1999-02-26) * |
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 14 22 December 1999 (1999-12-22) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004004673A1 (fr) * | 2002-07-08 | 2004-01-15 | Coty B.V. | Produit cosmetique anti-vieillissement cutane |
CN1297249C (zh) * | 2002-07-08 | 2007-01-31 | 科蒂股份有限公司 | 抗皮肤老化的化妆品 |
US8034385B2 (en) | 2002-07-08 | 2011-10-11 | Coty B.V. | Anti-ageing skin cosmetic |
Also Published As
Publication number | Publication date |
---|---|
AU3051900A (en) | 2000-08-01 |
US20080003311A1 (en) | 2008-01-03 |
JP4441123B2 (ja) | 2010-03-31 |
CA2360488A1 (fr) | 2000-07-20 |
US20040037901A1 (en) | 2004-02-26 |
US20020048594A1 (en) | 2002-04-25 |
EP1146850A1 (fr) | 2001-10-24 |
JP2002534454A (ja) | 2002-10-15 |
FR2788435A1 (fr) | 2000-07-21 |
FR2788435B1 (fr) | 2002-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0953346B1 (fr) | Utilisation d'au moins un hydroxystilbène dans une composition raffermissante | |
EP1090628B1 (fr) | Utilisation du lycopène dans des compositions destinées à traiter les signes cutanés du vieillissement | |
EP1064931B1 (fr) | Composition cosmétique comprenant au moins un hydroxystilbene et de l'acide ascorbique | |
EP1195156A1 (fr) | Utilisation d'un extrait d'Ericaceae pour traíter les signes du vieillissement cutané | |
EP1242045B1 (fr) | Utilisation d'un extrait du genre vaccinium comme agent anti-glycation | |
WO2000041674A1 (fr) | Utilisation d'un extrait d'un vegetal du genre rosmarinus dans des compositions destinees a traiter les signes cutanes du vieillissement | |
FR2812544A1 (fr) | Utilisation d'au moins un extrait d'au moins un vegetal du genre salvia dans des compositions destinees a traiter les signes cutanes du vieillissement | |
EP0938891A1 (fr) | Composition cosmétique contenant de l'acide cinnamique ou de ses dérivés et son utilisation | |
EP1351661A1 (fr) | Utilisation d'au moins une sapogenine pour prevenir les signes du viellissement cutane | |
EP1275372A1 (fr) | Composition cosmétique ou dermatologique comprenant un dérivé de N-Acylaminoamide et un inhibiteur de métalloprotéinase | |
EP1331924B1 (fr) | Utilisation de beta-carotene et de lycopene pour traiter les signes cutanes du vieillissement via l'inhibition de l'expression de la metalloproteinase de type 1 de la matrice extracellulaire | |
EP1331925A2 (fr) | Utilisation de l'association d' un carotenoide et d'un isoflavonoide pour traiter les signes cutanes du vieillissement | |
FR2987998A1 (fr) | Composition cosmetique comprenant un systeme activateur de la proteine trf2 a action synergique constitue d'une association d'un extrait peptidique de soja et de levure et ses utilisations | |
WO2002034210A2 (fr) | Utilisation de l'association d'au moins un carotenoide et de vitamine c pour traiter les signes cutanes du vieillissement | |
WO2002034276A2 (fr) | Utilisation de l'association d'au moins un extrait d'au moins un vegetal du genre camellia et d'au moins un carotenoïde | |
WO2002034231A2 (fr) | Utilisation de l'association d'un extrait de rosmarinus et d'un carotenoide | |
FR2821549A1 (fr) | Utilisation d'un carotenoide pour traiter les signes du vieillissement | |
WO2002102346A1 (fr) | Utilisation d'au moins un derive de l'acide 10-hydroxy-2-decenoique dans des compositions destinees a traiter les signes cutanes du vieillissement | |
FR2799368A1 (fr) | Utilisation du lycopene dans des compositions destinees a traiter les signes cutanes du vieillissement | |
FR2999926A1 (fr) | Utilisations d'une substance inhibitrice de la methylation de l'adn pour stimuler la formation des fibres elastiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000900546 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09869740 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2360488 Country of ref document: CA Ref country code: CA Ref document number: 2360488 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 593288 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09904560 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000900546 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |